BRISBANE, Calif. Aug.09, 2024 - Vera Therapeutics, Inc.(Nasdaq: VERA), a pioneering biopharmaceutical company, made a significant announcement today that has far-reaching implications for its shareholders and the company’s future growth.The announcement detailed the granting of inducement awards to three new employees in the form of non-qualified stock options and restricted stock units (RSUs) under the Inducement Plan, thus reinforcing the company’s commitment to attracting top talent and driving innovation.
The Compensation Committee, responsible for administering compensation plans, approved the inducement awards on August 6, 2024.The committee views these awards as instrumental in attracting and retaining high-caliber individuals, which is essential for advancing the company’s mission.This decision is well-aligned with Nasdaq Listing Rule 5635(c)(4), which permits non-publicly traded companies like Vera Therapeutics to grant inducement awards to new hires without seeking shareholder approval.
The inducement awards include a non-qualified stock option that allows the purchase of 33,000 shares of Class A common stock and RSUs that en
Comments